Kymab, a Sanofi company, has focused on developing its unique antibody platforms to create a portfolio of therapeutics since its founding in 2010." title="" class="btn" data-container="body" data-html="true" data-id="424478" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#b3d4fc" tabindex="0" data-original-title="Kymab Ltd"> 1,179 9,859
Activities
Technologies
Entity types
Location
The Bennet Building (B930), Babraham Research, Campus, Cambridge CB22 3AT, UK
Cambridge
United Kingdom
Employees
Scale: 51-200
Estimated: 39
Engaged corporates
4Added in Motherbase
1 year, 9 months agoKymab, a Sanofi company, based in Cambridge UK, is working to provide novel solutions in drug and vaccine development.
Kymab, a Sanofi company, is a clinical-stage global biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available.
Kymab’s platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently.
Advanced Human Antibody Drug Discovery and Development, Drug Discovery, Fully Human Monoclonal Antibodies, and Drug Development
Kymab, based in Cambridge, UK, is working independently and with partners to provide novel solutions in drug and vaccine development. Using our unique technology, we rapidly develop broad diversity, high-quality human antibodies for treating challenging diseases. We are building a rich pipeline of assets in four main therapeutic spaces: immuno-oncology, inflammation, haematology and infectious diseases, with clinical studies expected to begin in 2017.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() Sofinnova Partners Financial Services | Sofinnova Partners Financial Services | Other 29 Sep 2023 | | |
![]() Illumina For Startups Startup accelerator & VC, Biotechnology, Biotechnology Research | Illumina For Startups Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 27 Mar 2020 | | |
![]() Teva Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Teva Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Other 30 Mar 2020 | | |
![]() London Stock Exchange Finance, Financial Services | London Stock Exchange Finance, Financial Services | Other 26 Jan 2017 | |